• By ICR Secretariat
  • Posted Wednesday, July 12, 2023

With FDA approval in hand, BioMarin lays out plan to sell $2.9M gene therapy


BioMarin Pharmaceutical, having secured a long-awaited approval from the Food and Drug Administration, says its focus has now turned to launching its new hemophilia gene therapy in the U.S. market.